Insmed

Insmed focuses on rare pulmonary diseases, with an approved therapy for nontuberculous mycobacterial lung disease. The company's inhaled liposomal amikacin represents innovative drug delivery for difficult-to-treat lung infections. Insmed exemplifies the growing focus on orphan diseases and specialty pharmaceuticals.